XML 28 R52.htm IDEA: XBRL DOCUMENT v3.20.1
License agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 125 Months Ended
Apr. 30, 2016
Sep. 30, 2014
Jan. 31, 2010
Dec. 31, 2009
Nov. 30, 2009
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Mar. 31, 2020
Dec. 31, 2019
License agreements                      
Revenues           $ 568,507 $ 497,857        
JAKAFI                      
License agreements                      
Revenues           459,479 375,611        
Novartis                      
License agreements                      
Upfront and immediate milestone payment to be received under license agreement         $ 210,000            
Upfront payment received under license agreement       $ 150,000              
Immediate milestone payment received under license agreement     $ 60,000                
Reimbursable costs included in accounts receivable           100       $ 100 $ 400
Research and development expenses reimbursed           300 600        
Product royalties in accounts receivable           56,300       56,300 65,000
Novartis | Pre-specified Events | Maximum                      
License agreements                      
Upfront and immediate milestone payment to be received under license agreement         1,200,000            
Novartis | Development Milestones                      
License agreements                      
Amount recognized and received for the achievement of a predefined milestone                   132,000  
Novartis | Development Milestones | Maximum                      
License agreements                      
Upfront and immediate milestone payment to be received under license agreement         174,000            
Novartis | Regulatory Milestones                      
License agreements                      
Amount recognized and received for the achievement of a predefined milestone                   215,000  
Novartis | Regulatory Milestones | Maximum                      
License agreements                      
Upfront and immediate milestone payment to be received under license agreement         495,000            
Novartis | Commercialization Milestones                      
License agreements                      
Amount recognized and received for the achievement of a predefined milestone                   120,000  
Novartis | Commercialization Milestones | Maximum                      
License agreements                      
Upfront and immediate milestone payment to be received under license agreement         $ 500,000            
Novartis | Development and Commercialization Milestones                      
License agreements                      
Revenues           0 0        
Novartis | GVHD | Development Milestones | Phase III                      
License agreements                      
Amount recognized and received for the achievement of a predefined milestone                 $ 25,000    
Novartis | GVHD | Development and Regulatory Milestones | Maximum                      
License agreements                      
Upfront and immediate milestone payment to be received under license agreement $ 75,000                    
Novartis | JAKAFI | U.S.                      
License agreements                      
Royalties payable on net sales           17,500 13,400        
Royalties payable           56,300       $ 56,300 $ 50,200
Novartis | JAKAVI                      
License agreements                      
Revenues           $ 56,300 $ 45,600        
Novartis | JAKAVI | Minimum                      
License agreements                      
Royalty payments on future global net sales (as a percent)           12.00%          
Novartis | JAKAVI | Maximum                      
License agreements                      
Royalty payments on future global net sales (as a percent)           14.00%          
Novartis | JAKAVI | Regulatory Milestones | Europe                      
License agreements                      
Amount recognized and received for the achievement of a predefined milestone   $ 60,000                  
Novartis | JAKAVI | Commercialization Milestones                      
License agreements                      
Amount recognized and received for the achievement of a predefined milestone               $ 60,000 40,000    
Revenues               $ 900,000 $ 600,000